Get started
Author

Tapan N. Maniar

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
2014 · Max S Topp, Nicola Gökbuget, et al. · The Lancet Oncology · 1,268
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
2015 · Alison T. Stopeck, Karim Fizazi, et al. · Supportive Care in Cancer · 186
PDF
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
2016 · N Gökbuget, M Kelsh, et al. · Blood Cancer Journal · 125
PDF
Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy
2014 · Zachary Zimmerman, Tapan Maniar, et al. · International Immunology · 48
Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML
2023 · Martin Wermke, Stephan Metzelder, et al. · Blood · 41
Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
2014 · Max S. Topp, Nicola Goekbuget, et al. · Journal of Clinical Oncology · 22
An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab
2014 · Nicola Goekbuget, Hagop Kantarjian, et al. · Blood · 11
Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies
2009 · Tahamtan Ahmadi, Tapan Maniar, et al. · Current Treatment Options in Oncology · 10
Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
2014 · Anthony Stein, Max S. Topp, et al. · Blood · 7
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
2015 · Alison T. Stopeck, Karim Fizazi, et al. · Supportive Care in Cancer · 6
PDF
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.
2013 · Paul E. Goss, Carlos H. Barrios, et al. · Journal of Clinical Oncology · 6
Childhood ALL and second neoplasms
2007 · Tapan N. Maniar, Inbal Braunstein, et al. · Cancer Biology & Therapy · 6
PDF
Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.
2013 · Luis Costa, Karim Fizazi, et al. · Journal of Clinical Oncology · 3
Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial
2012 · R.E. Coleman, C. Barrios, et al. · Annals of Oncology · 3
Prognostic Factors for PTLD
2010 · Tapan Maniar, Donald Tsai · Springer eBooks · 3
Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study.
2015 · Hagop Kantarjian, Nicola Gökbuget, et al. · Journal of Clinical Oncology · 2
Abstract OT2-6-02: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial
2013 · PE Goss, CH Barrios, et al. · Cancer Research · 2
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.
2012 · Paul Edward Goss, Carlos H. Barrios, et al. · Journal of Clinical Oncology · 2
Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial
2012 · PE Goss, CH Barrios, et al. · Cancer Research · 1
OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE).
2011 · PE Goss, CH Barrios, et al. · Cancer Research · 1
Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.
2009 · Tahamtan Ahmadi, Elise A. Chong, et al. · Blood · 1
Blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: An open-label, single-arm, multicenter confirmatory phase 2 study
2014 · Topp, MS, Goekbuget, N, et al. · UCL Discovery (University College London)
Open-label, Single-arm, Multicenter Confirmatory Phase 2 Study of the Bite (r) Antibody Blinatumomab in Patients With Relapsed/refractory B-precursor Acute Lymphoblastic Leukaemia
2014 · Topp, M, Goekbuget, N, et al. · UCL Discovery (University College London)
Immunotherapy using bispecific T cell engager (BiTE®) antibodies: preclinical and clinical experience in acute leukemia
2014 · Marion Subklewe, Max Topp, et al. · Journal for ImmunoTherapy of Cancer
PDF
Comparing the Incidence of Acute Phase Reactions in Patients with Advanced Cancer and Bone Metastases or Muliple Myeloma Following Treatment with Denosumab or Zoledronic Acid: Results from a Combined Analysis of Three Phase 3 Randomized Trials
2012 · Jennifer J. Buechel, H. Polderdijk, et al. · ScholarSphere (Penn State Libraries)
Works count: 28
Citation count: 1,756
H-index: 8
I10-index: 8
Year
Topic
Type